Collaborating as partners to accelerate your research
Genome editing and gene modification technologies are becoming increasingly important for research and applied uses. In particular, the advent of Transcription Activator-Like (TAL) effectors and clustered regularly interspaced short palindromic repeats (CRISPRs) and CRISPR-associated (Cas) systems have revolutionized the field with their ease of use, design flexibility and utility in a variety of gene manipulations.
- Learn more about our genome editing tools
Many of our genome editing technologies and tools are available under license for use in a variety of commercial applications, including research services, contract manufacturing services, therapeutics and therapeutic bioproduction, vaccines, diagnostics, animal health, biofuels, and quality assurance/quality control. Please feel free to contact us to discuss how we might work together.
TAL Effectors
GeneArtâ„¢ TALs provide custom DNA-binding proteins for accurate DNA targeting and precise gene editing and gene regulation, enabling users to target any locus in the genome.
- Learn more about TAL-Based Genome Editing
The Thermo Fisher Scientific team has clarified a path for users to move confidently forward with GeneArt TALs in research and applied markets, by compiling a powerful intellectual property (IP) portfolio that includes not only the foundational IP originating from the University of Minnesota, Iowa State University, and Martin-Luther-Universitat Halle-Wittenberg, but also IP originating from Thermo Fisher Scientific, Cellectis AS, and others. Commercial licensing under this broad IP portfolio is available for most applied uses, including transgenic animal services, animal health, quality assurance/quality control, and production of biological materials, chemicals, and compounds for uses as diverse as therapeutics, vaccines, diagnostics, and fuels. In addition, this IP portfolio is available for commercial licensing for direct therapeutic use or cell therapy in selected indications.
Please contact us at outlicensing@thermofisher.com to learn more.
CRISPR-Cas9
The simplicity and flexibility of GeneArtâ„¢ CRISPR-Cas9 systems are revolutionizing the field of genome editing.
- Learn more about CRISPR-Based Genome Editing
To discuss commercial opportunities with our CRISPR-Cas products, please contact us at outlicensing@thermofisher.com.
RNAi
RNAi has proven to be a specific, potent and highly successful approach for loss-of-function studies in virtually all eukaryotic organisms.
- Learn more about RNAi
We offer Stealth RNAiâ„¢ technology for all research applications and additionally for commercial uses, including therapeutics, in conjunction with a commercial use license from Thermo Fisher Scientific. Stealth RNAiâ„¢ technology utilizes a proprietary structure, which uses modified chemical bases in a unique 25-base format.
Please contact us at outlicensing@thermofisher.com to learn more.
